Cargando…
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a difficult disease with high morbidity and mortality rates and lacks an effective treatment. Here, we report the therapeutic effect of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on hypertension + hyperlip...
Autores principales: | Zhang, Nannan, Feng, Bin, Ma, Xuexing, Sun, Kangyun, Xu, Guidong, Zhou, Yafeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702744/ https://www.ncbi.nlm.nih.gov/pubmed/31429767 http://dx.doi.org/10.1186/s12933-019-0914-1 |
Ejemplares similares
-
Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
por: Feng, Bin, et al.
Publicado: (2023) -
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020) -
Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
por: Stencel, Jason, et al.
Publicado: (2023) -
Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate–activated Citrate Synthase
por: Zhang, Xinxin, et al.
Publicado: (2023) -
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
por: Lewis, Gregory D., et al.
Publicado: (2023)